Portugal surrogacy: medical indications and donor requirements
Portugal: Law No. 90/2021 amended PMA Law No. 32/2006 from 1 January 2022. Qualifying medical conditions, required gamete, donor screening, missing regulation.
The legal rules exist, but the operating route remains unresolved
Law No. 90/2021 amended Portugal’s PMA statute, Law No. 32/2006, and entered into force on 1 January 2022. It sets surrogacy eligibility, gamete-source, documentation, prior authorization and carrier-protection rules. CNPMA still states that the regime awaits government regulation. No later promulgated regulation was identified in the official materials. A statutory rule should therefore not be treated as a currently usable authorization process. Before treatment, obtain current written confirmation from Portuguese counsel and CNPMA about whether and how applications are accepted.
Separately, Article 2 of Law No. 90/2021 states that the law applies to Portuguese nationals and foreign nationals with permanent residence in Portugal. This guide does not decide whether a particular applicant meets that separate personal-scope rule.
Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin applies generally from 7 August 2027, subject to provisions with different dates and transitional arrangements. For treatment planned on or after that date, donor-safety requirements and their interaction with Portuguese law must be rechecked.
Which medical condition can qualify?
Article 8(2) permits surrogacy only exceptionally and without payment for the pregnancy where the intended woman has no uterus, has a uterine injury or disease, or has another clinical condition that prevents her from carrying a pregnancy absolutely and permanently. The condition must prevent carrying a pregnancy, not merely make conception difficult. An infertility diagnosis, age, personal preference or clinic willingness to treat is not enough. Inability to produce viable eggs does not automatically establish inability to carry a pregnancy. “Another clinical condition” may require case-specific medical and legal interpretation, supported by records.
Article 39(1)–(2) provides criminal penalties for paid surrogacy contracts: for a beneficiary, up to two years’ imprisonment or a fine of up to 240 day-fines; for the carrier, a fine of up to 240 day-fines. Article 39(3)–(4) also penalizes gratuitous contracts outside the cases specified in Article 8(2), (4), (5), (7) and (8): for a beneficiary, up to one year’s imprisonment or a fine of up to 120 day-fines; for the carrier, a fine of up to 120 day-fines. Portuguese counsel must apply these provisions to the facts; a clinic’s acceptance or a private contract does not replace statutory compliance.
What must the medical file establish?
The law contemplates a joint application by the intended beneficiaries and the carrier. Supporting material includes their identification, acceptance of the proposed contract terms, medical documentation from the proposed PMA centre proving the Article 8(2) medical ground and Article 8(4) gamete rule, and a declaration from the centre director accepting treatment there. Prior CNPMA authorization is required, with consultation of the Portuguese medical and psychologists’ professional bodies. A medical report should identify the diagnosis, explain why it prevents pregnancy absolutely and permanently, and cite the supporting records; “infertility” alone is not enough. The centre’s declaration and medical records are not CNPMA authorization. Confirm current forms, required contents and submission route before filing.
At least one intended beneficiary must provide a gamete
Article 8(4) requires gametes from at least one intended beneficiary and prohibits the carrier from donating the oocyte used in the same procedure. Subject to Article 10’s separate donation conditions, a donor egg could be combined with a beneficiary’s sperm, or donor sperm with a beneficiary’s egg. A donor embryo made entirely from third-party gametes appears inconsistent with Article 8(4), because no beneficiary gamete would be used. Obtain a written, case-specific Portuguese opinion before relying on a proposed gamete combination.
When can donor eggs or sperm be used?
Article 10 allows donated oocytes, sperm or embryos where objectively available medical and scientific knowledge shows that pregnancy—or pregnancy without a serious genetic disease—cannot be achieved using the beneficiaries’ gametes, and effective conditions ensure gamete quality. In surrogacy, Article 8(4) still requires at least one beneficiary gamete. Donation is not a convenience-based option: the clinic should document the medical indication, quality safeguards and compliance with both provisions. A donor is not the child’s legal parent, but this parentage rule does not remove consent, screening, traceability or record-keeping duties.
Donor identity is not subject to an absolute secrecy guarantee. A person born following gamete or embryo donation may obtain relevant genetic information from health services; from age 18, they may request the donor’s civil identity from the CNPMA, and from age 16 they may ask whether a planned marriage faces a legal impediment. A court may also permit disclosure of donor identity for weighty reasons.
Donor screening and gamete safety are separate legal requirements
Law No. 12/2009 applies to reproductive cells and identifies CNPMA as the competent authority for the relevant quality-and-safety controls. For donors who are not partners of the recipient, Annex VII requires selection based on age, health and medical history, documented through a questionnaire and an in-person interview with an experienced doctor. For non-partner donations, a blood sample must be obtained at each donation. The statutory tests include HIV-1/2, hepatitis B, hepatitis C and syphilis; sperm donors must also test negative for Chlamydia by NAT on a urine sample. HTLV I/II testing is required for specified high-prevalence exposure links, and additional tests may be needed depending on medical history or the donated cells, for example RhD, malaria, CMV or T. cruzi. With the donor’s consent, genetic screening for autosomal-recessive genes prevalent in the donor’s ethnic background and assessment of inherited conditions known in the family are also required. Non-partner sperm donations must generally remain in quarantine for at least 180 days and then be retested using a new blood sample; the law provides an exception if the original sample was also tested for HIV, HBV and HCV by NAT. A further exception applies if processing includes a validated inactivation step for the relevant viruses. Risks and mitigation measures must be clearly explained to the recipient. Documentation and traceability are required. Ask the clinic for the applicable test panel, results and dates, any risk-based additions, the basis for any exception, and sample-traceability records. Additional clinic safeguards should be distinguished from the statutory minimum.
The carrier’s medical suitability and prior pregnancy history
The statute prefers a carrier who has already been a mother, but expressly allows that preference not to be met in a particular case; it is not an absolute requirement. Article 8 does not set a universal list of carrier diagnoses, fixed age limit or complete screening panel. Unless another binding source supports it, a clinic’s own criteria are policy, not legislation. The carrier has rights to appropriate care and accurate information about likely medical, psychological, social and legal implications, including pregnancy complications. She is entitled to psychological support before, during and after birth and to medical care for a pregnancy-related condition even where treatment may affect pregnancy viability. Her fundamental rights as a pregnant or postpartum woman remain protected.
What the law requires of the clinic and the consent process
Treatment must take place in a specifically authorized public or private PMA centre. Beneficiaries may refuse a technique with no reasonable prospect of success or significant risks to the health of the mother or child; they also have rights to suitable care and information about likely medical, social and legal implications. Consent must be free, informed, express and written. Before consent, beneficiaries must receive written information on all known benefits and risks and the ethical, social and legal implications. Both beneficiaries and the carrier must receive written information about how the carrier’s lifestyle may affect embryo and fetal development.
The arrangement must also be gratuitous. The beneficiaries may not impose obligations on, pay or give gifts to the carrier because of the pregnancy, except for properly documented expenses corresponding to health-care follow-up actually provided, including transport. Article 8 also bars an arrangement where the parties have a relationship of economic subordination, including an employment or service relationship. Do not assume that a flat fee or allowance falls within the narrow expense exception; obtain Portuguese legal advice on the proposed arrangement.
In the surrogacy contract, the statute requires clauses addressing obstetric guidance and necessary examinations or treatment, the carrier’s participation in decisions about the obstetrician and the type and place of birth, psychological support, the possible refusal of diagnostic tests such as amniocentesis, travel and lifestyle matters, health complications affecting the carrier or fetus, lawful pregnancy termination, failed attempts, withdrawal of consent, expenses and dispute resolution. The contract cannot impose terms that infringe the carrier’s statutory rights. Consent is not irrevocable merely because treatment has begun: under the amended text, the carrier may revoke it up to the child’s registration.
Statutory rule or clinic policy? A practical comparison
Use this comparison when reviewing a clinic’s eligibility list. It separates binding statutory rules from clinic policy; a clinic cannot waive a statutory condition by accepting a patient or donor.
| Issue | What the statute says | What should not be assumed |
|---|---|---|
| Medical indication | The intended woman’s pregnancy must be prevented absolutely and permanently by absence of uterus, uterine injury/disease or another clinical condition. | Any infertility diagnosis, age or personal preference automatically qualifies. |
| Gamete source | At least one intended beneficiary’s gamete must be used; the carrier cannot donate the egg used in that procedure. | A plan using only third-party gametes is compatible with surrogacy. |
| Third-party donation | Donation is subject to Article 10’s medical-scientific conditions and gamete-quality safeguards. | A donor can be selected merely for convenience, or without the required quality checks. |
| Carrier history | Previous motherhood is expressed as a preference, not an unconditional requirement. | Every carrier must have previously given birth, or an old clinic policy is current law. |
| Screening and clinic | Authorized PMA centre, statutory safety rules, appropriate information, consent and medical care are required. | Article 8 itself sets one universal test panel, age limit or embryo-transfer quota. |
| Authorization | The law contemplates prior CNPMA authorization and medical documents from the proposed centre. | A clinic’s willingness or a signed private contract replaces official authorization. |
| Payment and relationship | The arrangement must be gratuitous; only properly documented expenses for health-care follow-up actually provided, including transport, are excepted. Economic subordination, including employment or service relationships, bars the arrangement. | Do not assume a flat fee, allowance, gift, or employment/service relationship is lawful because a clinic accepts it. |
Documents and questions to prepare before committing
Before signing an agency agreement, paying a non-refundable deposit, creating embryos or arranging a transfer, ask for the following in writing:
- An up-to-date statement from Portuguese counsel and the CNPMA on whether a surrogacy application can currently be submitted, which rules and forms are being applied, and what the approval sequence is.
- A specialist medical report that identifies the intended woman’s condition and explains why it prevents pregnancy absolutely and permanently, with the underlying records and investigations.
- A written gamete plan naming whose oocyte and sperm will be used, whether any third-party donation is proposed, why donation is medically indicated, and how at least one intended beneficiary’s gamete will be used.
- The donor-selection, testing and traceability records for the proposed gametes, including blood-sample dates, results, risk-based tests and the basis for any quarantine/retesting exception; distinguish statutory requirements from additional clinic policy.
- Confirmation that the proposed PMA centre is specifically authorized, plus its written clinical eligibility and screening protocol for both the intended beneficiaries and the carrier.
- Draft informed-consent documents and contract clauses covering risks, obstetric care, diagnostic tests, psychological support, complications, termination, failed attempts, revocation of consent and expenses.
Practical conclusion
The statutory medical route is narrow: absence of a uterus, uterine injury or disease, or another clinical condition making pregnancy absolutely and permanently impossible. At least one intended beneficiary must contribute a gamete, the carrier cannot provide the egg, and any third-party donation must meet separate medical-necessity and quality rules. Donor assessment, testing, documentation and traceability are statutory safeguards. Official materials still leave the implementation route unresolved: Law No. 90/2021 is in force, but the regulation needed to operate its process has not been identified as promulgated. Do not assume a programme can accept or authorize a case. Obtain current written confirmation from CNPMA and independent Portuguese counsel before medical or financial steps, and recheck Regulation (EU) 2024/1938 for treatment on or after 7 August 2027.
Sources and legal materials
No later promulgated implementing regulation has been published; confirm the position before relying on this guide.
- Consolidated Law No. 32/2006 on medically assisted procreation [S1]
- Law No. 90/2021 amending the surrogacy regime [S2]
- CNPMA official guidance: Surrogacy [S3]
- Presidency: draft PMA regulation returned without promulgation, 13 January 2024 [S4]
- Parliament: Resolution Project 897/XVII/1, entered 3 May 2026 [S5]
- Law No. 12/2009 on quality and safety of human tissues and cells [S6]
- Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin [S7]
